Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for JANX011 (CD19 Bispecific) in Autoimmune Diseases. The expected timing is based on the latest available company guidance and may change.
02/17/26:- First participant dosed in Ph1 healthy volunteer trial evaluating safety, PK/PD and B-cell depletion. 02/26/26:- Phase 1 healthy volunteer trial actively enrolling; initial clinical update expected by year-end 2026. 05/07/26:- Phase 1 healthy volunteer trial actively enrolling; initial clinical update planned in second half 2026. 08/06/26:- Ph1 healthy volunteer study continues; initial clinical data expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.